{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:59Z","timestamp":1788922199587,"version":"build-2803163510"},"reference-count":44,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Objective: To report the rate of prescription opioid use rates over a 5-year period for the population of Newfoundland and Labrador (NL), Canada, and to highlight patient demographics within this cohort.\r\nDesign: This retrospective cohort design used population-based pharmacy network prescription data from the province of NL to identify patients who were prescribed opioids from June 1, 2017, to June 1, 2022.\r\nSetting: A cohort of adult and pediatric patients who were being prescribed opioids from June 1, 2017, to June 1, 2022, in NL.\r\nParticipants: Patients who were prescribed opioids from June 1, 2017, to June 1, 2022. Prescriptions without complete data and medications taken for pain control that were not defined as opioids were excluded from the analysis. Buprenorphine, buprenorphine\u2013naloxone, and methadone were also excluded from the analysis, as these are often prescribed as a treatment for opioid use disorder.\r\nResults: Between 27,344 (5.2 percent of NL population) and 57,562 (11 percent of NL population) opioid pain patients in NL were identified from 2017 to 2022, with 2018 having the highest number of opioid pain patients (11 percent). During this period, patients with opioid prescriptions averaged from 55 to 58 years of age. Data also showed more female users of prescription opioids than males, and there were no significant differences between urban and rural locations. The most prevalent type of prescriber during the period of observation was general practitioners (n = 1,131), followed by pharmacists (n = 476) and dentists (n = 237).\r\nConclusions: In comparison to national averages in Canada, NL had lower prescription opioid use rates. This study acts as a first step to better understand opioid use and prescribing practices in NL.<\/jats:p>","DOI":"10.5055\/jom.0889","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:44Z","timestamp":1755718484000},"page":"337-348","source":"Crossref","is-referenced-by-count":1,"title":["Population-based prescription opioid use rate in Newfoundland and Labrador: A retrospective cohort study"],"prefix":"10.5055","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-4706","authenticated-orcid":false,"given":"Cindy","family":"Whitten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobe","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Harnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooklyn","family":"Sparkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"96875","unstructured":"Public Health Agency of Canada: Apparent opioid and stimulant toxicity deaths: Surveillance of opioid and stimulant-related harms in Canada. 2023. Available at https:\/\/health-infobase.canada.ca\/src\/doc\/SRHD\/update_deaths_2023-12.pdf."},{"key":"96876","unstructured":"Canadian Centre of Substance Use and Addictions (CCSA): Prescription opioids (Canadian drug summary). 2020. Available at https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-07\/CCSACanadian-Drug-Summary-Prescription-Opioids-2020-en.pdf."},{"key":"96877","doi-asserted-by":"crossref","unstructured":"Howard R, Fry B, Gunaseelan V, et al.: Association of opioid prescribing with opioid consumption after surgery in Michigan [published correction appears in JAMA surg. 2019 Apr 1;154(4):368]. JAMA Surg. 2019; 154(1): e184234. DOI: 10.1001\/jamasurg.2018.4234.","DOI":"10.1001\/jamasurg.2018.4234"},{"key":"96878","doi-asserted-by":"crossref","unstructured":"Fischer B, Keates A, B\u00fchringer G, et al.: Non-medical use of prescription opioids and prescription opioid-related harms: Why so markedly higher in North America compared to the rest of the world? Addiction. 2014; 109(2): 177-181. DOI: 10.1111\/add.12224.","DOI":"10.1111\/add.12224"},{"key":"96879","unstructured":"Canadian Centre of Substance Use and Addictions (CCSA): Opioids (Canadian drug summary). 2022. Available at https:\/\/www.ccsa.ca\/sites\/default\/files\/2022-11\/CCSA-Canadian-Drug-Summary\u2013Opioids-2022-en.pdf."},{"key":"96880","doi-asserted-by":"crossref","unstructured":"Dunn KM, Saunders KW, Rutter CM, et al.: Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152(2): 85-92. DOI: 10.7326\/0003-4819-152-2-201001190-00006.","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"96881","doi-asserted-by":"crossref","unstructured":"Fischer B, Daldegan-Bueno D, Jones W: Comparison of crude population-level indicators of opioid use and related harm in New Zealand and Ontario (Canada). Pain Ther. 2021; 10(1): 15-23. DOI: 10.1007\/s40122-020-00229-6.","DOI":"10.1007\/s40122-020-00229-6"},{"key":"96882","unstructured":"Government of Canada: Opioids. 2023. Available at https:\/\/www.canada.ca\/en\/health-Canada\/services\/opioids.html."},{"key":"96883","doi-asserted-by":"crossref","unstructured":"Macintyre PE, Quinlan J, Levy N, et al.: Current issues in the use of opioids for the management of postoperative pain: A review. JAMA Surg. 2022; 157(2): 158-166. DOI: 10.1001\/jamasurg.2021.6210.","DOI":"10.1001\/jamasurg.2021.6210"},{"key":"96884","unstructured":"Carri\u00e8re G, Garner R, Sanmartin C: Significant factors associated with problematic use of opioid pain relief medications among the household population, Canada, 2018. Health Rep. 2021; 32(12): 13-26. DOI: 10.25318\/82-003-x202101200002-eng."},{"key":"96885","doi-asserted-by":"crossref","unstructured":"Dowell D, Ragan KR, Jones CM, et al.: Prescribing opioids for pain\u2014The new CDC clinical practice guideline. N Engl J Med. 2022; 387(22): 2011-2013. DOI: 10.1056\/NEJMp2211040.","DOI":"10.1056\/NEJMp2211040"},{"key":"96886","doi-asserted-by":"crossref","unstructured":"Kaye AD: Prescription opioid abuse in chronic pain: An updated review of opioid abuse predictors and strategies to curb opioid abuse: Part 1. Pain Phys. 2017; 2(20): s93-s109. DOI: 10.36076\/ppj.2017.s109.","DOI":"10.36076\/ppj.2017.s109"},{"key":"96887","doi-asserted-by":"crossref","unstructured":"Cobaugh DJ, Gainor C, Gaston CL, et al.: The opioid abuse and misuse epidemic: Implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm. 2014; 71(18): 1539-1554. DOI: 10.2146\/ajhp140157.","DOI":"10.2146\/ajhp140157"},{"key":"96888","doi-asserted-by":"crossref","unstructured":"Von Korff M, Kolodny A, Deyo RA, et al.: Long-term opioid therapy reconsidered. Ann Intern Med. 2011; 155(5): 325-328. DOI: 10.7326\/0003-4819-155-5-201109060-00011.","DOI":"10.7326\/0003-4819-155-5-201109060-00011"},{"key":"96889","doi-asserted-by":"crossref","unstructured":"Rudd RA, Seth P, David F, et al.: Increases in drug and opioid-involved overdose deaths\u2014United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65(50-51): 1445-1452. DOI: 10.15585\/mmwr.mm655051e1.","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"96890","doi-asserted-by":"crossref","unstructured":"Grecu AM, Dave DM, Saffer H: Mandatory access prescription drug monitoring programs and prescription drug abuse. J Policy Anal Manag. 2019; 38(1): 181-209.","DOI":"10.1002\/pam.22098"},{"key":"96891","unstructured":"Sansone RA, Sansone LA: Doctor shopping: A phenomenon of many themes. Innov Clin Neurosci. 2012; 9(11-12): 42-46."},{"key":"96892","doi-asserted-by":"crossref","unstructured":"Biernikiewicz M, Taieb V, Toumi M: Characteristics of doctor-shoppers: A systematic literature review. J Mark Access Health Policy. 2019; 7(1): 1595953. DOI: 10.1080\/20016689.2019.1595953.","DOI":"10.1080\/20016689.2019.1595953"},{"key":"96893","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016; 315(15): 1624-1645. DOI: 10.1001\/jama.2016.1464.","DOI":"10.1001\/jama.2016.1464"},{"key":"96894","doi-asserted-by":"crossref","unstructured":"McCabe SE, West BT, Morales M, et al.: Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 2007; 102(12): 1920-1930. DOI: 10.1111\/j.1360-0443.2007.02015.x.","DOI":"10.1111\/j.1360-0443.2007.02015.x"},{"key":"96895","doi-asserted-by":"crossref","unstructured":"Cheatle MD: Prescription opioid misuse, abuse, morbidity, and mortality: Balancing effective pain management and safety. Pain Med. 2015; 16(Suppl. 1): S3-S8. DOI: 10.1111\/pme.12904.","DOI":"10.1111\/pme.12904"},{"key":"96896","doi-asserted-by":"crossref","unstructured":"Dowell D, Regan KR, Jones CM, et al.: CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022. MMWR Recomm Rep. 2022; 71(3): 1-95. DOI: 10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"96897","doi-asserted-by":"crossref","unstructured":"Han B, Compton WM, Blanco C, et al.: Prescription opioid use, misuse, and use disorders in US adults: 2015 national survey on drug use and health. Ann Intern Med. 2017; 167(5): 293-301. DOI: 10.7326\/M17-0865.","DOI":"10.7326\/M17-0865"},{"key":"96898","doi-asserted-by":"crossref","unstructured":"Odani S, Lin LC, Nelson JR, et al.: Misuse of prescription pain relievers, stimulants, tranquilizers, and sedatives among US older adults aged \u226550 years. Am J Prev Med. 2020; 59(6): 860-872. DOI: 10.1016\/j.amepre.2020.04.028.","DOI":"10.1016\/j.amepre.2020.04.028"},{"key":"96899","doi-asserted-by":"crossref","unstructured":"Premachandran P, Nippak P, Begum H, et al.: Opioid prescribing practices in trauma patients at discharge: An exploratory retrospective chart analysis. Medicine (Baltimore). 2022; 101(42): e31047. DOI: 10.1097\/MD.0000000000031047.","DOI":"10.1097\/MD.0000000000031047"},{"key":"96900","doi-asserted-by":"crossref","unstructured":"Rusu D: Overdose escalation and the COVID-19 pandemic: An urgent reminder to innovate Canada's response to the opioid crisis. Univ Western Ontario Med J. 2021; 89(S). DOI: 10.5206\/uwomj.v89iS1.10917.","DOI":"10.5206\/uwomj.v89iS1.10917"},{"key":"96901","unstructured":"Preuss CV, Kalava A, King KC: Prescription of controlled substances: Benefits and risks. In StatPearls. Treasure Island, FL: StatPearls Publishing, 2023."},{"key":"96902","unstructured":"Government of Canada: Chronic pain. 2023. Available at https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/chronic-pain\/about-chronic-pain.html."},{"key":"96903","unstructured":"Government of Canada: Canadian alcohol and drugs survey (CADS): Summary of results for 2019. 2023. Available at https:\/\/www.canada.ca\/en\/health-canada\/services\/canadian-alcoholdrugs-survey\/2019-summary.html."},{"key":"96904","doi-asserted-by":"crossref","unstructured":"Fischer B, Varatharajan T, Shield K, et al.: Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug Alcohol Depend. 2018; 189: 76-79. DOI: 10.1016\/j.drugalcdep.2018.04.024.","DOI":"10.1016\/j.drugalcdep.2018.04.024"},{"key":"96905","unstructured":"Statistics Canada: Exploring the intersectionality of characteristics among those who experienced opioid overdoses: A cluster analysis. Health Reports. 2023. Available at https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-003-x\/2023003\/article\/00001-eng.htm."},{"key":"96906","doi-asserted-by":"crossref","unstructured":"Srivastava AB, Mariani JJ, Levin FR: New directions in the treatment of opioid withdrawal. Lancet. 2020; 395(10241): 1938-1948. DOI: 10.1016\/S0140-6736(20)30852-7.","DOI":"10.1016\/S0140-6736(20)30852-7"},{"key":"96907","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"96908","doi-asserted-by":"crossref","unstructured":"Kuntz JL, Dickerson JF, Schneider JL, et al.: Factors associated with opioid-tapering success: A mixed methods study. J Am Pharm Assoc (2003). 2021; 61(3): 248-257.e1. DOI: 10.1016\/j.japh.2020.12.019.","DOI":"10.1016\/j.japh.2020.12.019"},{"key":"96909","doi-asserted-by":"crossref","unstructured":"Sanyal C: Economic burden of opioid crisis and the role of pharmacist-led interventions. J Am Pharm Assoc. 2021; 61(3): e70-e74. DOI: 10.1016\/j.japh.2020.11.006.","DOI":"10.1016\/j.japh.2020.11.006"},{"key":"96910","unstructured":"Public Health Agency of Canada: Opioid and stimulant poisoning hospitalizations: Surveillance of opioid and stimulant-related harms in Canada. 2023. Available at https:\/\/health-infobase.canada.ca\/src\/doc\/SRHD\/Update_Hospitalizations_2023-12.pdf."},{"key":"96911","unstructured":"Public Health Agency of Canada: Suspected opioid-related overdoses: Based on emergency medical services. 2023. Available at https:\/\/health-infobase.canada.ca\/src\/doc\/SRHD\/Update_EMS_2023-12.pdf."},{"key":"96912","unstructured":"Canadian Substance Use Costs and Harms [CSUCH]: Substance use costs in Canada in 2020. 2020. Available at https:\/\/csuch.ca\/substance-use-costs\/current-costs\/#:~:text=How%20substance%20use%20costs%20in%20Canada%20changed%20between,from%20%241%2C154%20in%202007%20to%20%241%2C291%20in%202020."},{"key":"96913","doi-asserted-by":"crossref","unstructured":"Jalali MS, Botticelli M, Hwang RC, et al.: The opioid crisis: A contextual, social-ecological framework. Health Res Policy Syst. 2020; 18(1): 87. DOI: 10.1186\/s12961-020-00596-8.","DOI":"10.1186\/s12961-020-00596-8"},{"key":"96914","doi-asserted-by":"crossref","unstructured":"Park JN, Rouhani S, Beletsky L, et al.: Situating the continuum of overdose risk in the social determinants of health: A new conceptual framework. Milbank Q. 2020; 98(3): 700-746. DOI: 10.1111\/1468-0009.12470.","DOI":"10.1111\/1468-0009.12470"},{"key":"96915","doi-asserted-by":"crossref","unstructured":"Dasgupta N, Beletsky L, Ciccarone D: Opioid crisis: No easy fix to its social and economic determinants. Am J Public Health. 2018; 108(2): 182-186. DOI: 10.2105\/AJPH.2017.304187.","DOI":"10.2105\/AJPH.2017.304187"},{"key":"96916","unstructured":"IBM Corp.: IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp., 2021: 28."},{"key":"96917","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: ATC\/DDD index. 2021. Available at https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed October 7, 2022."},{"key":"96918","doi-asserted-by":"crossref","unstructured":"Vashishtha D, Mittal ML, Werb D: The North American opioid epidemic: Current challenges and a call for treatment as prevention. Harm Reduct J. 2017; 14(1): 2017. DOI: 10.1186\/s12954-017-0135-4.","DOI":"10.1186\/s12954-017-0135-4"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3890\/4175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3890\/4175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:56Z","timestamp":1755718496000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,20]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0889","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}